Oric Pharmaceuticals, Inc. (ORIC)
7.36
-0.34
(-4.42%)
USD |
NASDAQ |
Nov 20, 16:00
7.35
-0.01
(-0.14%)
After-Hours: 20:00
Oric Pharmaceuticals Enterprise Value : 506.43M for Nov. 20, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 20, 2026 | 506.43M |
| November 19, 2026 | 541.74M |
| November 18, 2026 | 536.55M |
| November 17, 2026 | 572.90M |
| November 16, 2026 | 523.05M |
| November 13, 2026 | 558.36M |
| November 12, 2026 | 624.83M |
| November 11, 2026 | 676.77M |
| November 10, 2026 | 667.42M |
| November 09, 2026 | 700.66M |
| November 06, 2026 | 658.07M |
| November 05, 2026 | 623.80M |
| November 04, 2026 | 712.08M |
| November 03, 2026 | 738.05M |
| November 02, 2026 | 684.04M |
| October 30, 2026 | 701.70M |
| October 29, 2026 | 675.73M |
| October 28, 2026 | 707.93M |
| October 27, 2026 | 676.77M |
| October 26, 2026 | 672.09M |
| October 23, 2026 | 1.110B |
| October 22, 2026 | 1.158B |
| October 21, 2026 | 1.181B |
| October 20, 2026 | 1.173B |
| October 19, 2026 | 1.063B |
| Date | Value |
|---|---|
| October 16, 2026 | 1.025B |
| October 15, 2026 | 1.068B |
| October 14, 2026 | 945.78M |
| October 13, 2026 | 916.70M |
| October 12, 2026 | 968.63M |
| October 09, 2026 | 987.33M |
| October 08, 2026 | 991.48M |
| October 07, 2026 | 989.40M |
| October 06, 2026 | 986.29M |
| October 05, 2026 | 1.039B |
| October 02, 2026 | 1.010B |
| October 01, 2026 | 1.042B |
| September 30, 2026 | 1.141B |
| September 29, 2026 | 1.124B |
| September 28, 2026 | 1.114B |
| September 25, 2026 | 1.102B |
| September 24, 2026 | 1.104B |
| September 23, 2026 | 1.120B |
| September 22, 2026 | 1.138B |
| September 21, 2026 | 1.052B |
| September 18, 2026 | 1.064B |
| September 17, 2026 | 1.073B |
| September 16, 2026 | 1.038B |
| September 15, 2026 | 1.020B |
| September 14, 2026 | 1.050B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.052B |
| Alnylam Pharmaceuticals, Inc. | 18.66B |
| Anika Therapeutics, Inc. | 158.39M |
| Savara, Inc. | 776.30M |
| Arrowhead Pharmaceuticals, Inc. | 6.053B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -48.08M |
| Total Expenses (Quarterly) | 48.08M |
| EPS Diluted (Quarterly) | -0.4444 |
| Earnings Yield | -19.90% |
| Normalized Earnings Yield | -19.90 |